Policy Update Validates Clinical Value and Expands Patient Access to Innovative Chronic Rhinitis Treatment
Aerin Medical Inc., a leader in minimally invasive solutions for chronic nasal conditions, announced that Cigna Healthcare will provide coverage for RhinAer treatment of the posterior nasal nerve. This change removes RhinAer from Cigna’s list of procedures deemed experimental, investigational, and unproven, marking a significant step forward in expanding access to a best-in-class treatment option for patients suffering from the debilitating effects of chronic rhinitis.
Health Technology Insights: Craft Telemedicine Launches to Redefine Specialty Care with Human-Centered Platform
Starting September 15, over 15 million Cigna members and their healthcare providers will gain access to this clinically proven solution for patients with chronic rhinitis, a persistent inflammatory condition that significantly compromises quality-of-life. Cigna’s policy update highlights the growing recognition of RhinAer’s clinical efficacy and net health benefit as a non-invasive alternative to surgery or long-term, ineffective medication and clinic-based management.
Health Technology Insights: Gold Coast Health Plan Awards Grants to Expand Ventura Care
“Cigna’s decision is a pivotal milestone in expanding physician and patient access to RhinAer — already used to treat more than 50,000 patients,” said Matt Brokaw, CEO of Aerin Medical. “Alongside recent coverage expansion by Blue Cross of Idaho, this momentum underscores the compelling evidence for this procedure and its significant benefit for sufferers. We are grateful for our partnership with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and EVP/CEO Dr. Rahul K. Shah, MD, MBA, and for the significance of our combined voice in elevating awareness of this condition’s burden.”
“Chronic rhinitis takes a substantial toll on patients and Cigna’s decision is a welcome development that empowers physicians to offer critical solutions to appropriate patients,” said Dr. Gavin Setzen, CEO & President of Albany ENT & Allergy Services, P.C., and Associate Clinical Professor of Otolaryngology-Head & Neck Surgery at Albany Medical Center, and past president of AAO-HNS. “With strong evidence from 20 peer-reviewed publications and multi-study evidence of three-year durability, we know that RhinAer works. I am pleased that Cigna’s decision supports the adoption of a therapy that elevates the standard of care for patients.”
Health Technology Insights: Star Health and Medi Assist Partner to Transform Claims with AI
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
